# Colony Morphology & ID {-}

Community-acquired pneumonia (CAP), healthcare-associated pneumonia (HCAP), and infections in cystic fibrosis (CF) patients are distinct clinical entities with unique diagnostic and therapeutic considerations. Understanding these differences is crucial for effective patient management

## **Community-Acquired Pneumonia (CAP)** {-}

*   **Definition:** Pneumonia acquired outside of a healthcare setting
*   **Common Pathogens**
    *   ***Streptococcus pneumoniae***: Most common cause
    *   *Haemophilus influenzae*
    *   *Moraxella catarrhalis*
    *   *Legionella pneumophila*: Less common but important
    *   *Staphylococcus aureus*: Less common
*   **Diagnostic Approach**
    *   **Sputum:** Sputum collection
    *   **Gram Stain:** Quality is assessed. Provides initial diagnostic information
    *   **Culture:** On BAP and CHOC. Culture allows the identification of the organisms
    *   **Special Tests:** *Legionella*
    *   **Other Tests:** Blood cultures
*   **Key Considerations**
    *   Patient age, underlying medical conditions
    *   Severity of illness
    *   Presence of complications

## **Healthcare-Associated Pneumonia (HCAP)** {-}

*   **Definition:** Pneumonia that develops in a patient with specific healthcare exposures, or with certain risk factors
*   **Pathogens**
    *   **High Risk of MDROs:** Multidrug-resistant organisms (MDROs) are more common
    *   ***Acinetobacter baumannii* complex**
    *   *Enterobacteriaceae* (e.g., *Klebsiella pneumoniae*)
    *   *Pseudomonas aeruginosa*
    *   *Stenotrophomonas maltophilia*
    *   *Staphylococcus aureus*
*   **Diagnostic Approach**
    *   **Specimen Sources:** Sputum, ETA, BAL
    *   **Quantitative cultures may be used**
    *   **Culture and Gram stain on different types of media:** including BAP, CHOC, and selective media
    *   **Antimicrobial Susceptibility Testing:** Essential to guide treatment
*   **Key Considerations**
    *   Risk factors
    *   Presence of MDROs
    *   Prompt antibiotic therapy

## **Cystic Fibrosis (CF)** {-}

*   **Chronic, Polymicrobial Infections:** Chronic infections
*   **Pathogens**
    *   ***Pseudomonas aeruginosa***: The most common, chronic
    *   *Staphylococcus aureus*: Early colonizer
    *   *Haemophilus influenzae*
    *   *Burkholderia cepacia* complex (*Bcc*): Serious, transmissible
*   **Diagnostic Approach**
    *   **Specimen Sources:** Sputum, BAL
    *   **Sputum Quality:** This should be assessed
    *   **Culture**
        *   BAP and CHOC
        *   Selective media for *Bcc*
        *   Incubation times
        *   Antimicrobial Susceptibility Testing
    *   **Identification:** Species identification for *Bcc*
*   **Key Considerations**
    *   Chronic infections
    *   Polymicrobial
    *   Antibiotic resistance
    *   Airway clearance

## **Key Differentiators** {-}

| Feature             | CAP                                  | HCAP                                      | Cystic Fibrosis (CF)                     |
| :------------------ | :----------------------------------- | :---------------------------------------- | :--------------------------------------- |
| Setting             | Community                              | Healthcare                                | Chronic disease with respiratory involvement |
| Common Pathogens   | *S. pneumoniae, H. influenzae*        | MDROs: *Acinetobacter, Enterobacteriaceae, Pseudomonas, S. aureus* | *Pseudomonas aeruginosa, S. aureus, Haemophilus influenzae, Burkholderia cepacia* complex |
| Antibiotic Resistance | Less common                            | More common                               | Common, especially *Pseudomonas*          |
| Specimen Source     | Sputum                               | Sputum, ETA, BAL                         | Sputum, BAL                               |
| Reporting           | Gram stain, culture, ID               | Gram stain, culture, quantitative/semi-quantitative, ID, AST  | Gram stain, culture, ID, AST            |
| Additional factors  | Patient's health and clinical status     | Healthcare risk, patient history         | CF-specific issues and patient history   |

## **Role of the Laboratory** {-}

*   **Provide Accurate and Timely Results:** The lab plays a crucial role in the diagnosis and management
*   **Employ Appropriate Methods:** Labs must use the right methods
*   **Communicate Effectively:** All lab results must be communicated
